Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of

Status Completed

Clinical Trial Summary

Streptococcus pneumoniae, also known as Pneumococcus, is a common cause of pneumonia in transplant patients. There has been a vaccine available for this infection called Pneumovax. Recently, a new vaccine for this infection called Prevnar has been developed which may be more effective. Vaccinating the bone marrow donor before transplant may boost the recipient's immune response to the vaccine after transplant. This study is done to compare how vaccinating the donor with one of the vaccines will affect the recipient's immune system response to the vaccine.

Clinical Trial Description

This is a randomized controlled trial designed to assess the immunogenicity of the new pneumococcal conjugate vaccine in a cohort of allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. This will be done by using an approach of pre-transplant donor immunization with post-transplant recipient immunization. Response will be compared with the standard 23-valent polysaccharide vaccine. It is hypothesized that the conjugate vaccine will provide an enhanced response in this group of immunosuppressed individuals who respond poorly to standard polysaccharide vaccines.

Specific objectives of this study are:

- To determine the antibody response to both vaccines via a measurement of total antibody response and by the opsonophagocytic assay. This assay has the advantage of assessing if patient antibody responses represent truly functional antibodies that display opsonic activity against pneumococcus and is likely better correlated with protective efficacy.

- To determine any acute adverse reactions of the conjugate vaccine in this population. Results of this trial will help lay the foundation for the development of a rationale and optimal pneumococcal vaccination strategy that would prevent significant morbidity in this patient population.

We hypothesize that pneumococcal conjugate vaccine, due to its T-cell dependent response will have greater immunogenicity and protective effect in an allo-HSCT population by using a donor immunization strategy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

Bone Marrow Transplant

Clinical Trial Details

NCT number	NCT00143780
Study type	Interventional
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	Phase 4
Start date	May 2002
Completion date	July 2006

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02451462` - Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients	N/A
Completed	`NCT03654599` - Effects of Digital Stories Intervention on Psychosocial Well-being	N/A
Active, not recruiting	`NCT04395222` - Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation	Phase 2
Not yet recruiting	`NCT05603156` - A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive	N/A
Completed	`NCT03530969` - Geriatric Communication Skills Training Program for Oncology Clinicians	N/A
Recruiting	`NCT04115241` - Activity Levels in Bone Marrow Transplant Patients
Completed	`NCT05662631` - Remote Monitoring and Home-based Health Care for Treatment of Bone Marrow Transplant Patients	N/A
Completed	`NCT03028961` - Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant	N/A
Completed	`NCT02575079` - Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT	N/A
Active, not recruiting	`NCT02665065` - Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia	Phase 3
Completed	`NCT01735565` - Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant	N/A
Completed	`NCT04041219` - Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients	Phase 4
Not yet recruiting	`NCT06361173` - Spanish BMT4me Usability & Acceptability
Completed	`NCT03030248` - Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients	Phase 2
Completed	`NCT00695123` - Screening for Subjects to Participate in Studies of Blood Disorders
Terminated	`NCT02057289` - A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis	Phase 1
Completed	`NCT04275830` - The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients	N/A
Completed	`NCT03902210` - BMT Online Wellness Study	N/A
Completed	`NCT03245788` - Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study	N/A
Completed	`NCT03758911` - Perspectives on Bone Marrow Donors Who Donate for Their Parent

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms